Erytech Pharma Inc.

165 articles with Erytech Pharma Inc.

• ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL

  7/29/2021

  ERYTECH Pharma (Nasdaq & Euronext: ERYP),a clinical-stage biopharmaceutical company, leader in red blood-cell based cancer therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL)patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).

• ERYTECH to Participate in the BTIG Virtual Biotechnology Conference

  7/27/2021

  ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that Chief Executive Officer, Gil Beyen, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 9th.

• Report - Erytech’s Combined Shareholders’ Meeting on June 25, 2021

  6/25/2021

  ERYTECH Pharma announced that its 2021 Annual General Meeting was held in Lyon on Friday, June 25, 2021.

• Erytech’s Combined Shareholders’ Meeting on June 25, 2021

  5/25/2021

  Erytech Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, is announcing that its Combined Shareholders’ Meeting will be held in French in closed session at 2pm CEST on Friday, June 25, 2021, and also the associated details.

• ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

  12/14/2020

  A total of 510 patients enrolled Events required to trigger interim superiority analysis accrued Interim superiority analysis expected in Q1 2021; final analysis in Q4 2021

• ERYTECH to Present at the JMP Securities Hematology Summit

  12/10/2020

  ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announce d today that CEO, Gil Beyen, will present at t he JMP Securities Hematology Summit Tuesday December 15 th at 1: 3 0pm EST /0 6 : 3 0pm GMT / 7 : 3 0pm CET . The format will be a “fireside chat” d

• ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting

  12/7/2020

  The study confirms the potential of eryaspase as an attractive treatment option for ALL patients with hypersensitivity to PEG-asparaginase

• ERYTECH Announces Conference Webcast to Discuss Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia to be Presented at the American Society of Hematology 2020 Annual Meeting

  12/3/2020

  ERYTECH Pharma (Nasdaq & Euronext: ERYP),a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announcesa webcast scheduled for investors to discuss the results from the NOPHO sponsored Phase 2 trial of eryaspase in ALL patients.

• ERYTECH to Present at Jefferies Virtual Healthcare Conference

  11/12/2020

  ERYTECH Pharma (Nasdaq & Euronext: ERYP), announced t o day that its CEO, Gil Beyen, will present an update at the Jefferies Virtual London Healthcare Conference at 12 :00 pm EST / 05:00pm GMT / 6 :00 pm CET on November 18, 2020. A webcast of the event will be available on ERYTECH’s website at www.erytech.com/investors/webcast/ About ERYTECH and eryaspase ERYTECH is a clinical-stage biopharmaceu

• ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2020

  11/5/2020

  ERYTECH Pharma,a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, provided a business and financial update.

• ERYTECH Announces Abstract with Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Selected for Oral Presentation at the American Society of Hematology 2020 Annual Meeting

  11/5/2020

  Oral presentation to discuss findings from the Nordic Society of PaediatricHaematology and Oncology(NOPHO)-sponsored Phase 2trial that confirm the potential of eryaspase as a treatment option for ALL

• ERYTECH Secures €10 Million in Non-Dilutive Financing, Guaranteed by the French Government

  11/2/2020

  Approvals received from Bpifrance and SociétéGénéralefor a total of EUR 10 million in non-dilutive financing in the form of a State-Guaranteed Loan (PGE Loan)

• ERYTECH to Host Third Quarter 2020 Conference Call and Business Update on November 6, 2020

  10/29/2020

  ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells , t oday announced that it will host a Third Quarter 20 20 conference call  and webcast on Friday, November 6 , 20 20 , at 2:30 PM CET/8:30 AM EST to discuss operational highlights. The call is accessible via the below teleconfere

• ERYTECH Appoints Stewart Craig as Chief Technical Officer

  10/26/2020

  ERYTECH Pharma (Nasdaq & Euronext: ERYP),a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced the appointment of Dr. Stewart Craig as its Chief TechnicalOfficer (CTO) and member of the executive team.

• ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2020Conference call and webcast on Tuesday, September 22 at 2:30 pm CET/8:30 am ET

  9/21/2020

  TRYbeCA-1 Phase 3 trial in second-line metastatic pancreatic cancer: More than 90% of the planned 500 patients enrolled Fast-Track designation granted by U.S. FDA Interim superiority analysis expected in Q1 2021 ; final analysis in 2H of 2021 NOPHO-sponsored Phase 2 trial in second-line acute lymphoblastic leukemia: Completed patient enrollment : 55 patients enrolled Encouraging interim results: target level and duration of asparaginase activity reached

• ERYTECH establishes a financing facility with the implementation of an at-the-market program on Nasdaq with Cowen

  9/21/2020

  ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances in red blood cells (the "Company"), today announced the implementation of an at-the-market program allowing the Company to issue and sell ordinary shares in the form of American Depositary Shares ("ADSs"), to eligible investors at market prices, with aggregate gross sales proceeds of

• ERYTECH to Host on September 22, 2020 Second Quarter 2020 Conference Call and Business Update

  9/16/2020

  ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter 2020 conference call and webcast on Tuesday, September 22, 2020, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights. The call is accessible via the below teleconferencing numbers, f

• ERYTECH Announces the Hosting of a KOL Event as the TRYbeCA-1 Phase 3 Trial in Second-line Pancreatic Cancer Nears Complete Enrollment

  9/14/2020

  ERYTECH Pharma (Nasdaq & Euronext: ERYP),a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announces the hosting of a Key Opinion Leader (KOL) Event to discuss the medical need in pancreatic cancer and the potential role of eryaspase in this setting

• ERYTECH Reports Voting Results from its Annual General Meeting Held on June 26, 2020

  6/26/2020

  ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP) announced that its 2020 Annual General Meeting was held in Lyon on Friday, June 26, 2020. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: -   Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2019; -   Allocation of the financial year's r

• ERYTECH extends its cash horizon by implementing a convertible bond financing

  6/25/2020

  Agreement with Alpha Blue Ocean and European High Growth Opportunities Securitization Fund for the issuance of zero-coupon convertible notes with share warrants attached